Andrew Mignatti, Co-Founder and CEO of careviso, looks at the possibility of the United States (US) adopting international reference pricing and asks if it is possible to lower drug costs without undermining innovation. Discussion around international reference pricing (IRP) is intensifying as policymakers search for ways to… Read More
Adityo Prakash, CEO of Verseon, introduces a new mathematical approach to computing molecular interactions. The objective of small-molecule drug discovery is to find binders to target proteins involved in disease processes. However, the discovery and development of novel small-molecule therapeutics remains one of the most resource-intensive endeavors… Read More
On International Clinical Trials Day, Lars Erwig, Director of the Centre for Drug Development at Cancer Research UK, calls for an international approach to clinical trials. Launching a clinical trial for a new cancer treatment is a formidable challenge. For one thing, patient recruitment is arguably… Read More
DDW’s Megan Thomas hears from industry experts Daniel Veres, Turbine’s Chief Scientific Officer & Co-Founder, as well as Ryan Jacobs, Business Development Manager at Astoriom, about AACR 2025. MT: What do you consider to be the key trends in cancer research? Daniel Veres: Key trends in cancer research include a… Read More
Dr Jeff Domsic, Product Manager Charles River Laboratories, discusses ATP-bioluminescence testing aligned with new regulatory guidelines. Over the past decade, the emergence of advanced therapy medicinal products (ATMPs) has fundamentally changed the approach to developing, manufacturing, administering, and treating diseases. These advanced modalities show significant promise… Read More
It seems rather obvious, and somewhat unfair to DDW’s readers – considering how much he has been in the news recently – to talk more about President Donald Trump and specifically his decision to cut billions of dollars in funding to the National Institutes of Health (NIH). The decision… Read More
Rare Disease Day is an observance held on the last day of February annually to raise awareness for rare diseases and improve access to treatment and medical representation for individuals with rare diseases and their families. To mark Rare Disease Day 2025, DDW gathered insight from a range of industry… Read More
Advanced Therapies Week (ATW) 2025 took place Dallas, US, from 20-23 January 2025. DDW’s Megan Thomas hears from industry experts in attendance and reports on news from the event. Patient perspective Michalle Adkins, Director of Life Sciences Strategy and Direction at Emerson USA, said: “One of the most exciting things… Read More
Dr Tim Meyer, University Medical Center Göttingen, explains the case for automation in labs and what’s stopping the technology from being implemented. Anyone who’s worked in cell culture or on any repetitive laboratory task knows the dream of automation—whether it is to increase efficiency or just to minimise human error. Read More
In one of his first acts as President, Donald Trump signed an executive order to withdraw the US from the World Health Organization (WHO). DDW’s Megan Thomas spoke with three industry leaders to understand the impact this will have on the drug development sector. Cell and gene therapy According… Read More
An opinion by Dr Ioannis Papasotiriou. This article is sponsored by RGCC International. How is a new drug developed in oncology? While this may seem like a simple question, it is important to recognise that the process is far more complex than it initially… Read More
Nathan Yee, Senior Director of CMC Portfolio Strategy at Tune Therapeutics, and Lucas Thompson, Senior Director of Research at Tune Therapeutics, discuss the opportunities and challenges in cell therapy. Cell therapy is a transformative medical approach that harnesses living cells as therapeutic agents and has demonstrated the potential to address… Read More
DDW’s Megan Thomas reflects on the impact of AbbVie’s failed schizophrenia trials. Earlier this month, AbbVie provided updates confirming that its two Phase II EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute exacerbation of psychotic symptoms, have failed in… Read More
DDW’s Multimedia Editor Megan Thomas attended the Society for Neuroscience (SfN)’s Neuroscience 2024 in October 2024 in Chicago, US. Having published a general event roundup, here she unpacks the ‘Animals in Research’ panel: Lifesaving clinical advances stemming from animal research, which took place on Monday 7 October. Read More
Max Baumann, Co-Founder and Head of Execution of Treehill Partners, discusses what investors, drug developers, and the rest of the life science sector can do to prepare for the Trump/RFK era. The arrival of a new US administration generates significant industry-wide speculation and anticipation regarding new policies and agendas that may… Read More
Professor Trevor Jones, Co-Chair of the Cannabinoid Research and Development Group (CRDG), discusses how the UK could become a leader in cannabinoid research. The UK is a global leader in biotechnology and one of the top countries for cannabinoid R&D – only Canada and the US publish more cannabinoid research. Read More
